Calmune Tackles Difficult Antigenic Targets: Firm Strives to Exploit Antibody Structures Made by the Body

摘要

Conventional antibody discovery methods poorly detect antigens cloaked in carbohydrates or lipids. Scientists at Calmune (www.calmune.com) in San Diego are creating new technology platforms that overcome such limitations to uncover potent antibodies against infectious viruses, bacteria, and fungi. "Calmune offers new ways to generate antibodies against targets that have not adequately been addressed by conventional technologies," says president and CEO Anthony Williamson, Ph.D.Some of the technology under development at Calmune was licensed from the Scripps Research Institute, where Dr. Williamson was an associate professor. He left Scripps and co-founded Calmune in 2006 along with colleagues Dennis Burton, Ph.D., and Pietro Paolo Sanna, Ph.D. The three researchers collaborated at Scripps on investigations into human antibody responses to infectious pathogens using phage-display libraries.